Mantinex

Memantine hydrochloride, the active ingredient in Mantinex, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Mantinex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantinex is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

Alzheimer’s disease (moderate to severe): improves cognition, daily living activities and overall clinical status. Alzheimer’s disease (moderate): supports maintenance of functional abilities. Alzheimer’s disease (severe): helps slow further cognitive decline.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: occasional tension‑type headache. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or low energy. - Nausea: mild upset stomach. - Cough: dry or non‑productive cough.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Severe allergic reaction: rash, itching, swelling, or breathing difficulty. - Hallucinations: visual or auditory disturbances. - Mood changes: depression or suicidal thoughts. - Hyponatremia: low blood sodium levels. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, consider patient history, concomitant conditions, and monitoring requirements. - Renal impairment: dose may need adjustment; monitor kidney function. - Hepatic disease: use with caution; assess liver enzymes. - Cardiovascular disease: monitor blood pressure and heart rate. - Psychiatric disorders: observe for mood changes or hallucinations. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring careful assessment.

Major Interactions (Avoid): - Amantadine: combined use can increase risk of dizziness and confusion. - Ketamine: additive NMDA antagonism may enhance neuropsychiatric effects. - High‑dose quinidine: may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce therapeutic benefit. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Proton pump inhibitors: may slightly increase memantine exposure. - Antihypertensives: monitor blood pressure for additive effects.